Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease

Robert M Burkes,1,2 Ralph J Panos1,2 1University of Cincinnati Division of Pulmonary, Critical Care, and Sleep Medicine, Cincinnati, OH, USA; 2Department of Pulmonary, Critical Care, and Sleep Medicine, Cincinnati Veterans’ Affairs Medical Center, Cincinnati, OH, USACorrespondence: Ralph J...

Full description

Bibliographic Details
Main Authors:	Burkes RM, Panos RJ
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-12-01
Series:	Journal of Experimental Pharmacology
Subjects:	chronic obstructive pulmonary disease (copd) beta agonist long acting beta-agonist (laba) ultra long acting beta-agonist (ulaba)
Online Access:	https://www.dovepress.com/ultra-long-acting-beta-agonists-in-chronic-obstructive-pulmonary-disea-peer-reviewed-fulltext-article-JEP

Similar Items

Experience with the triple fixed combination in patients with chronic obstructive pulmonary disease
by: I. V. Demko, et al.
Published: (2022-01-01)

ICS/formoterol in the management of asthma in the clinical practice of pulmonologists: an international survey on GINA strategy
by: Álvaro A. Cruz, et al.
Published: (2021-01-01)

Long-acting Bronchodilators in COPD Management: One or Two?
by: Konstantinos Kostikas, et al.
Published: (2023-01-01)

Maintenance Therapy for Children and Adolescents with Asthma: Guidelines and Recommendations from the Emilia-Romagna Asthma (ERA) Study Group
by: Valentina Fainardi, et al.
Published: (2023-08-01)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
by: Kang J, et al.
Published: (2017-12-01)

Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment
by: Celli BR, et al.
Published: (2019-05-01)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β2-agonist via dry-powder inhalers and pressurized metered-dose inhalers
by: Wittbrodt ET, et al.
Published: (2018-12-01)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
by: Tariq SM, et al.
Published: (2017-06-01)

Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy
by: Hongyu Wang, et al.
Published: (2018-05-01)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
by: Albertson TE, et al.
Published: (2019-06-01)

Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease
by: Takahashi K, et al.
Published: (2021-12-01)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
by: Liao PA, et al.
Published: (2023-04-01)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
by: Czira A, et al.
Published: (2023-04-01)

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
by: Heinrich Worth, et al.
Published: (2021-04-01)

Striving for optimal bronchodilation: focus on olodaterol
by: Incorvaia C, et al.
Published: (2016-03-01)

Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells
by: Nan Yang, et al.
Published: (2021-02-01)

Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis
by: Reza Karbasi-Afshar, et al.
Published: (2016-04-01)

Perfil de un paciente con enfermedad obstructiva crónica tratado con la combinación de un agonista β2 adregénico de acción prolongada y un corticoide inhalado en un dispositivo presurizado en la práctica clínica habitual: estudio ARIES
by: Jorge Arencibia-Borrego, et al.
Published: (2023-04-01)

Impulse Oscillometry; Therapeutic Impacts of Transdermal Long-Acting Beta-2 Agonist Patch in Elderly Asthma with Inhaled Corticosteroid Alone
by: Hiroshi Tanaka, et al.
Published: (2012-01-01)

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
by: Tashkin DP
Published: (2020-11-01)

Beta-adrenergic and M-cholinergic receptor interactions in the pathogenesis of bronchial obstructive pulmonary diseases
by: Anna V. Eremenko, et al.
Published: (2020-10-01)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
by: Donohue JF, et al.
Published: (2017-01-01)

Pharmacotherapeutic strategy for COPD patients: focus on dual bronchodilators
by: A. I. Sinopalnikov
Published: (2021-10-01)

Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It
by: Nicolas Vertadier, et al.
Published: (2022-03-01)

Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework
by: Chun-Yu Chen, et al.
Published: (2023-09-01)

Retrospective assessment of a collaborative digital asthma program for Medicaid-enrolled children in southwest Detroit: reductions in short-acting beta-agonist (SABA) medication use
by: Meredith Barrett, et al.
Published: (2023-05-01)

Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article
by: Faeq R. Kukhon, et al.
Published: (2021-05-01)

Inhalation of Budesonide/Formoterol Increases Diaphragm Muscle Contractility
by: Chiyohiko Shindoh, et al.
Published: (2012-01-01)

Characteristics of patients with asthma overprescribed short-acting beta-agonist (SABA) reliever inhalers stratified by blood eosinophil count in North East London: a cross-sectional observational study
by: Paul Pfeffer, et al.
Published: (2023-06-01)

Normalisation of airflow limitation in asthma: Post‐hoc analyses of TRIMARAN and TRIGGER
by: Alberto Papi, et al.
Published: (2022-04-01)

Treatment after a COPD exacerbation
by: Robbins RA
Published: (2013-07-01)

NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY
by: S. N. AVDEEV
Published: (2016-12-01)

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
by: Gary T. Ferguson, et al.
Published: (2020-05-01)

Experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2021-01-01)

Discovering the Relative Efficacy of Inhaled Medications for Chronic Obstructive Pulmonary Disease: Multiple Treatment Comparisons
by: Ying Zhu, et al.
Published: (2017-03-01)

An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients
by: Rahul Sharma, et al.
Published: (2021-01-01)

Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis
by: R. Agarwal, et al.
Published: (2016-01-01)

Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
by: Richard Beasley, et al.
Published: (2019-12-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey
by: Mannino D, et al.
Published: (2022-04-01)